References
- AdeloyeD, ChuaS, LeeC, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05.02041526755942
- FerkolT, SchraufnagelD. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404–406. doi:10.1513/AnnalsATS.201311-405PS24673696
- Website of the European Respiratory Society - European Lung White Book. Available from: https://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/. Accessed 917, 2019.
- O’DonnellDE, LamM, WebbKA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):542–549. doi:10.1164/ajrccm.160.2.990103810430726
- ZuWallackRL, MahlerDA, ReillyD, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119(6):1661–1670. doi:10.1378/chest.119.6.166111399688
- BelmanMJ, BotnickWC, ShinJW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(3):967–975. doi:10.1164/ajrccm.153.3.86305818630581
- COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105(5):1411–1419. doi:10.1378/chest.105.5.14118181328
- JonesPW, BoshTK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155(4):1283–1289. doi:10.1164/ajrccm.155.4.91050689105068
- VinckenW, van NoordJA, GreefhorstAP, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19(2):209–216. doi:10.1183/09031936.02.0023870211871363
- CasaburiR, MahlerDA, JonesPW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224. doi:10.1183/09031936.02.0026980211866001
- MiravitllesM, SicrasA, CrespoC, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis. 2013;7(3):139–150. doi:10.1177/175346581348408023653458
- RabeKF, HurdS, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO17507545
- SalinasGD, WilliamsonJC, KalhanR, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171–179.21468169
- PalmiottiGA, LacedoniaD, LiotinoV, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462.30147311
- JochmannA, NeubauerF, MiedingerD, SchafrothS, TammM, LeuppiJD. General practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD cohort study. Swiss Med Wkly. 2010;140.
- SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-201930846476
- JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
- MahlerDA, WellsCK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.5803342669
- MillerMR, HankinsonJ, BrusascoV, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
- MacintyreN, CrapoRO, ViegiG, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735. doi:10.1183/09031936.05.0003490516204605
- VestboJ, HurdSS, AgustiAG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
- DecramerM Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2014 [ updated 2014]; Available from: http://www.goldcopd.org. Accessed 318, 2020.
- AlifanoM, CuvelierA, DelageA, et al. Treatment of COPD: from pharmacological to instrumental therapies. Eur Respir Rev. 2010;19(115):7–23. doi:10.1183/09059180.0000800920956161
- ChanKP, KoFW, ChanHS, et al. Adherence to a COPD treatment guideline among patients in Hong Kong. Int J Chron Obstruct Pulmon Dis. 2017;12:3371–3379. doi:10.2147/COPD.S14707029238182
- PerezX, WisniveskyJP, LurslurchachaiL, KleinmanLC, KronishIM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106(3):374–381. doi:10.1016/j.rmed.2011.09.01022000501
- FerraraR, IentileV, PiccinniC, et al. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. NPJ Prim Care Respir Med. 2018;28(1):10. doi:10.1038/s41533-018-0077-729572448
- YangIA, FongKM, SimEH, BlackPN, LassersonTJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;2:CD002991.
- BrusselleG, PriceD, Gruffydd-JonesK, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217. doi:10.2147/COPD.S9169426527869
- WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
- Cabrera LopezC, Casanova MacarioC, Marin TrigoJM, et al. Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. Am J Respir Crit Care Med. 2018;197(4):463–469. doi:10.1164/rccm.201707-1363OC29099607
- KressJP, PohlmanAS, AlverdyJ, HallJB. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med. 1999;160(3):883–886. doi:10.1164/ajrccm.160.3.990205810471613